<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519749</url>
  </required_header>
  <id_info>
    <org_study_id>4D-310-C001</org_study_id>
    <nct_id>NCT04519749</nct_id>
  </id_info>
  <brief_title>An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males With Fabry Disease</brief_title>
  <official_title>An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4D Molecular Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4D Molecular Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter, open-label, dose-escalation trial to assess the safety,&#xD;
      tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study&#xD;
      population is comprised of adult males with Fabry Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter, open-label, dose-escalation trial to assess the safety,&#xD;
      tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study&#xD;
      population is comprised of adult males with Fabry Disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Safety and tolerability of 4D-310 following a single IV dose, as assessed by incidence and severity of adverse events, serious adverse events and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum AGA activity</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline in serum AGA activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood leukocyte AGA activity</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline in blood leukocyte AGA activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum globotriaosylsphingosine (lysoGb3)</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline serum globotriaosylsphingosine (lysoGb3)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV administration of 4D-310 Dose Level 1 - AAV NAb Titer Group A patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 1 - AAV NAb Titer Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV administration of 4D-310 Dose Level 1 - AAV NAb titer Group B patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 2 - AAV NAb Titer Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV administration of 4D-310 Dose Level 2 - AAV NAb titer Group A patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Level 2 - AAV NAb Titer Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV administration of 4D-310 at Dose Level 2 in AAV NAb titer Group B patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-310 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4D-310</intervention_name>
    <description>4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).</description>
    <arm_group_label>4D-310 Dose Expansion</arm_group_label>
    <arm_group_label>4D-310 Dose Level 1 - AAV NAb Titer Group B</arm_group_label>
    <arm_group_label>4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A</arm_group_label>
    <arm_group_label>4D-310 Dose Level 2 - AAV NAb Titer Group A</arm_group_label>
    <arm_group_label>4D-310 Dose Level 2 - AAV NAb Titer Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male ≥ 18 years of age&#xD;
&#xD;
          2. Pathogenic GLA mutation consistent with Fabry Disease&#xD;
&#xD;
          3. Confirmed diagnosis of classic Fabry disease with one or more clinical&#xD;
             characteristics: acroparesthesia, hypohidrosis, angiokeratoma or cornea verticillata,&#xD;
             or late-onset Fabry disease with left ventricular hypertrophy.&#xD;
&#xD;
          4. Individuals on ERT must be on a stable dose for at least 6 months (and a minimum of 12&#xD;
             months total exposure) prior to study enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of high titer NAb to 4D-310 capsid&#xD;
&#xD;
          2. eGFR &lt;45 mL/min/1.73 m2&#xD;
&#xD;
          3. Undergone kidney transplantation or currently on hemodialysis or peritoneal dialysis&#xD;
&#xD;
          4. Either history of, or a positive serology test at Screening for hepatitis B surface&#xD;
             antigen (HBsAg), hepatitis C antibody (HCAb), or human immunodeficiency virus (HIV)&#xD;
&#xD;
          5. Evidence of liver disease&#xD;
&#xD;
          6. Severe pulmonary disease&#xD;
&#xD;
          7. Diabetes with poor glycemic control&#xD;
&#xD;
          8. History of stroke or transient ischemic attack within the last 12 months, or other&#xD;
             significant thromboembolic disease history (e.g. pulmonary embolism)&#xD;
&#xD;
          9. Contraindication to systemic corticosteroid therapy or immunosuppressive therapy&#xD;
&#xD;
         10. Chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within the last&#xD;
             12 months.&#xD;
&#xD;
         11. Moderately severe to severe cardiovascular disease&#xD;
&#xD;
         12. Uncontrolled hypertension&#xD;
&#xD;
         13. Left ventricular ejection fraction of &lt;45% on echocardiogram (ECHO)&#xD;
&#xD;
         14. Currently receiving investigational drug, device or therapy or having ever received&#xD;
             gene therapy&#xD;
&#xD;
         15. History of infusion related response to ERT or any adverse reaction leading to ERT&#xD;
             discontinuation&#xD;
&#xD;
         16. History of cancer within 2 years (exceptions include non-melanoma skin cancer,&#xD;
             localized prostate cancer treated with curative intent)&#xD;
&#xD;
         17. Presence of intercurrent illness or other extenuating circumstance including active&#xD;
             infection, active illicit drug or alcohol abuse; that might limit compliance with&#xD;
             study requirements; morbid obesity with a BMI of &gt;=35; or in the Investigator's&#xD;
             assessment would place the subject at an unacceptable risk or confound interpretation&#xD;
             of results&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Schiffmann, MD, MHSc, FAAN</last_name>
    <role>Study Director</role>
    <affiliation>4D Molecular Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Nie</last_name>
    <phone>510-505-2680</phone>
    <email>clinicaltrials@4DMT.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Chacana, MSN, RN</last_name>
      <phone>205-934-7649</phone>
      <email>tchacana@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Wallace, MD, FASN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Jacob Laney</last_name>
      <phone>404-778-8518</phone>
      <email>dawn.laney@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Wilcox, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadene Henderson</last_name>
      <phone>412-692-3475</phone>
      <email>nadene.henderson@chp.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michele Graham</last_name>
      <email>michele.graham@chp.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gerard Vockley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Bailey</last_name>
      <email>Carrie.Bailey@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicola Longo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lysosomal &amp; Rare Disorders Research &amp; Treatment Center, Inc</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rekha Gopal</last_name>
      <phone>571-732-4606</phone>
      <email>rgopal@ldrtc.org</email>
    </contact>
    <investigator>
      <last_name>Ozlem Goker-Alpan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Nervous System Brain Diseases</keyword>
  <keyword>Metabolic</keyword>
  <keyword>Inborn Brain Diseases</keyword>
  <keyword>Metabolic Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Cerebral Small Vessel Diseases</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>X-Linked</keyword>
  <keyword>Inborn</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Sphingolipidoses</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Inborn Errors</keyword>
  <keyword>Lipodoses</keyword>
  <keyword>Lipid Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

